By Brad Sorensen, CFA
NASDAQ: LGVN
READ THE FULL LGVN RESEARCH REPORT
Longeveron (NASDAQ: LGVN) is a clinical-stage biotechnology company that has positioned itself in the regenerative medicine space with a potentially life-changing therapeutic candidate. Its flagship product, laromestrocel, is an allogeneic medicinal-signaling cell (MSC) therapy derived from young healthy adult donors and manufactured under current good manufacturing practice. The science behind laromestrocel rests on the idea that these MSCs may provide anti-inflammatory, pro-vascular, and regenerative support in tissues that are damaged or under stress. The company behind these exciting developments is at an inflection point in our view, with a good opportunity to achieve many of the goals discussed in the near future.
The company released its full-year 2025 financial results, which showed revenues of $1.2 million and a gross profit of $0.8 million, both in line with expectations and a positive for a company still in the clinical stage. The company also confirmed, due to the recent financing actions that we wrote about, current cash on hand should fund operating and capital expenditures into 4Q2026, which would be past the projected critical release of test results. The company also noted that, while the trial for HLHS treatment by laromestrocel remains the top priority, LGVN is also pursuing multiple other paths for conditions such as Alzheimer’s Disease and Pediatric Dilated Cardiomyopathy with its signature treatment.
We also want to remind investors about the progress made on treating HLHS, which is a rare and life-threatening congenital heart defect in which the left ventricle is severely underdeveloped or absent, meaning that the right ventricle must be adapted to handle systemic circulation. Even with the standard of care—typically a series of three reconstructive surgeries over the first few years of life—survival into adolescence is only around 50–60%.
Longeveron’s approach has been to administer laromestrocel directly into the right ventricle (or the myocardium of the right ventricle) during the second stage of surgery (the “Glenn” procedure, typically at around 4 months of age). Company scientists believe that by improving the function of the systemic right ventricle—through regenerative mechanisms—the therapy should improve transplant-free survival and long-term outcomes for these infants.
The company reported Phase 1 results (called ELPIS I) in ten infants. In that study, laromestrocel was well tolerated: there were no major adverse cardiovascular events or infections related to therapy through one year, meeting the primary safety endpoint. Even more striking, long-term follow-up showed 100 % transplant-free survival up to five years in those patients, compared to historical controls (approximately 83 % at five years, with ~5 % requiring transplant) in the comparable population.
Building on that, Longeveron is now conducting a pivotal Phase 2b trial (ELPIS II-mentioned above). The trial is designed to compare Laromestrocel plus standard surgery versus standard surgery alone, with endpoints including survival at 12 months, length of hospitalization, and change in right ventricular ejection fraction between baseline and 12 months. Full enrollment was achieved in June 2025, with topline results, as mentioned above, anticipated in the third quarter of 2026 after a 12-month follow-up.
On the regulatory front, the program has very strong designations. The U.S. Food and Drug Administration has approved three special designations for laromestrocel in the HLHS indication: Rare Pediatric Disease (RPD) designation, Orphan Drug Designation (ODD), and Fast Track designation. Importantly, following a Type C meeting with the FDA in September 2024, the agency confirmed that the ELPIS II trial could serve as a pivotal study—and if positive, could form the basis for a Biologics License Application (BLA) submission for full traditional approval.
In Alzheimer’s disease, Longeveron is positioning laromestrocel as a potentially disease-modifying therapy targeting neuroinflammation, which is increasingly understood to be a key driver of cognitive decline. Clinical evidence from the Phase 2a CLEAR MIND trial showed that treatment was associated with reduced neuroinflammation, slowed cognitive and functional decline, and measurable preservation of brain structure, including reduced brain volume loss and improved cerebral blood flow. These results support the company’s hypothesis that a multi-mechanistic cell therapy can address several aspects of Alzheimer’s pathology simultaneously, including immune dysregulation and vascular impairment. Building on these findings, Longeveron has aligned with the FDA on a path toward a single pivotal Phase 2/3 trial that, if successful, could support a Biologics License Application. The program has also received Regenerative Medicine Advanced Therapy (RMAT) and Fast Track designations, underscoring both the unmet need and the perceived potential of the therapy. The company is now seeking partnerships or non-dilutive funding to initiate this late-stage study, with timing currently anticipated in the second half of 2026.
In parallel, Longeveron’s PDCM program reflects a more accelerated regulatory pathway driven by the severity and rarity of the disease. Pediatric dilated cardiomyopathy is a life-threatening condition with limited treatment options, where a significant proportion of patients require heart transplantation or die within a short period after diagnosis. Here, laromestrocel is intended to improve cardiac function by promoting tissue repair, reducing inflammation, and enhancing vascularization within the heart muscle. Following FDA acceptance of its Investigational New Drug (IND) application in mid-2025, the company is permitted to move directly into a single Phase 2 pivotal registration trial, bypassing earlier-stage studies typically required in broader indications. This trial is expected to begin in 2027 and could serve as the primary basis for potential approval if successful.
Summary
We continue to believe that Longeveron is an exciting clinical-stage company, and investors aren’t appropriately appreciating the game-changing potential laromestrocel may be able to have on multiple serious medical conditions. As a result of the prudent decisions made by management, we believe laromestrocel will ultimately have a substantial impact on the health situations of thousands of patients. We believe the stock continues to be underpriced as investors aren’t appreciating the potential of laromestrocel and encourage investors to take a look at LGVN.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.